KPL-716-C201: A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis

To evaluate the efficacy of subcutaneous (SC) KPL-716 in reducing pruritis in subjects with moderate to severe PN experiencing severe itching.

Kiniska Pharmaceuticals, Ltd.
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Contact Phone Number
Request Information